晚期卵巢癌新辅助化疗的潜在候选人群:基于年龄、分期与肿瘤范围的生存分析
该回顾性队列研究利用SEER数据库2010–2016年III–IV期高级别浆液性卵巢癌女性数据,采用倾向评分逆概率加权评估新辅助化疗(NACT)与初始肿瘤细胞减灭术(PCS)的生存差异。结果显示,老年、IV期及更大肿瘤范围患者中NACT与PCS的总生存相似,而年轻、III期及较小范围患者中NACT总生存更差。
要点
- 老年(≥65岁)患者中NACT与PCS总生存相似(HR 1.07,95%CI 0.95-1.20,P=0.284)。
- IV期患者中NACT与PCS总生存相似(HR 0.96,95%CI 0.84-1.10,P=0.564)。
- 年轻、III期及较小肿瘤范围患者中NACT总生存劣于PCS。
核心结论
- 晚期卵巢癌NACT的生存效应可能因患者和肿瘤因素而异,老年、IV期及更大肿瘤范围患者中NACT与PCS总生存相似。
研究设计与样本
- 回顾性队列研究,查询美国国家癌症研究所SEER项目2010–2016年III–IV期高级别浆液性卵巢癌女性。
- 采用倾向评分逆概率治疗加权评估年龄、癌症分期和肿瘤范围特异性的NACT生存估计。
主要发现
- NACT使用在老年女性(≥65岁;相对增加48.4%)、IV期(相对增加35.2%)和III期(相对增加25.0%)中显著增加(所有P-trend<0.05)。
- 老年女性中NACT与PCS总生存相似(HR 1.07,95%CI 0.95-1.20,P=0.284)。
- IV期疾病中NACT与PCS总生存相似(HR 0.96,95%CI 0.84-1.10,P=0.564)。
- 更大疾病范围(T3/N1/M1)中NACT与PCS总生存相似(HR 1.06,95%CI 0.84-1.32,P=0.640)。
- 年轻组(HR 1.22,95%CI 1.07-1.38,P=0.004)、III期(HR 1.26,95%CI 1.13-1.41,P<0.001)及较小疾病范围(T3/N0/M0,HR 1.38,95%CI 1.20-1.58,P<0.001)中NACT总生存劣于PCS。
临床怎么用
- 对于老年、IV期或肿瘤范围更大的晚期高级别浆液性卵巢癌患者,NACT可作为与PCS总生存相似的选项。
- 对于年轻、III期或肿瘤范围较小的患者,优先考虑PCS而非NACT。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To examine trends and outcomes related to neoadjuvant chemotherapy (NACT) use for advanced ovarian cancer based on patient and tumor factors. METHODS: This retrospective cohort study queried the National Cancer Institute's Surveillance, Epidemiology, and End Results Program to examine women with stage III-IV high-grade serous ovarian carcinoma from 2010 to 2016. Propensity score inverse probability of treatment weighting was used to assess the age-, cancer stage-, and tumor extent-specific survival estimates related to NACT use. RESULTS: Utilization of NACT has significantly increased in older women (≥65 years; 48.4% relative increase), followed by stage IV disease (35.2% relative increase), and stage III disease (25.0% relative increase) (all, P-trend < 0.05). Women who received NACT had overall survival (OS) similar to those who had primary cytoreductive surgery (PCS) in older women (hazard ratio [HR] 1.07, 95% confidence interval [CI] 0.95-1.20, P = 0.284), stage IV disease (HR 0.96, 95%CI 0.84-1.10, P = 0.564), and more disease extent cases (T3/N1/M1, HR 1.06, 95%CI 0.84-1.32, P = 0.640). Moreover, NACT use was associated with decreased other cause mortality risk compared to PCS in the older women (sub-distribution HR 0.61, 95%CI 0.40-0.94, P = 0.025) and stage IV disease (sub-distribution HR 0.49, 95%CI 0.27-0.90, P = 0.021). In contrast, women who received NACT had decreased OS compared to those who had PCS in the younger group (HR 1.22, 95%CI 1.07-1.38, P = 0.004), stage III disease (HR 1.26, 95%CI 1.13-1.41, P < 0.001), and lesser disease extent cases (T3/N0/M0, HR 1.38, 95%CI 1.20-1.58, P < 0.001). CONCLUSION: Our study suggests that survival effect of NACT for advanced ovarian cancer may differ based on patient and tumor factors. In older women, stage IV disease, and greater disease extent, NACT was associated with similar OS compared to PCS.
引用
- Matsuo K, Matsuzaki S, Nusbaum DJ, et al. Possible candidate population for neoadjuvant chemotherapy in women with advanced ovarian cancer. Gynecol Oncol. 2020. PMID: 33196436. doi:10.1016/j.ygyno.2020.10.027
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。